Summary
Bristol-Myers Squibb Company (BMY) reported its first quarter 2012 financial results, showing an increase in Net Sales to $5.25 billion, up from $5.01 billion in the prior year's quarter. This growth was primarily driven by strong performance in key products like SUSTIVA, BARACLUDE, SPRYCEL, YERVOY, and ONGLYZA/KOMBIGLYZE, as well as favorable pricing in certain segments. Diluted Earnings Per Share (EPS) also saw an increase to $0.64, up from $0.57 in Q1 2011. However, the company faces significant headwinds with the expected loss of exclusivity for major products like AVAPRO*/AVALIDE* in March 2012 and PLAVIX* in May 2012, which are anticipated to cause a material decline in future sales and profitability. To mitigate these risks, BMY has been actively pursuing a strategy focused on advancing its pipeline, expanding biologics capabilities, and executing strategic acquisitions, such as the recent Inhibitex, Inc. acquisition to bolster its infectious disease pipeline. Investors should closely monitor the impact of patent expirations and the success of new product launches and pipeline developments.
Financial Highlights
58 data points| Revenue | $5.25B |
| Cost of Revenue | $1.30B |
| Gross Profit | $3.95B |
| R&D Expenses | $909.00M |
| SG&A Expenses | $1.00B |
| Operating Expenses | $3.22B |
| Operating Income | $1.40B |
| Interest Expense | $42.00M |
| Net Income | $1.10B |
| EPS (Basic) | $0.65 |
| EPS (Diluted) | $0.64 |
| Shares Outstanding (Basic) | 1.69B |
| Shares Outstanding (Diluted) | 1.71B |
Key Highlights
- 1Net Sales increased by 5% to $5.25 billion in Q1 2012 compared to $5.01 billion in Q1 2011, driven by volume and pricing.
- 2Diluted Earnings Per Share (EPS) rose to $0.64 from $0.57 in the prior year's quarter.
- 3The company acquired Inhibitex, Inc. for $2.5 billion to strengthen its infectious disease portfolio, particularly for Hepatitis C.
- 4Significant revenue growth was observed in YERVOY (154 million), SPRYCEL (34% increase), BARACLUDE (18% increase), and ONGLYZA/KOMBIGLYZE (99% increase).
- 5Loss of exclusivity for AVAPRO*/AVALIDE* occurred in March 2012 and for PLAVIX* is expected in May 2012, leading to anticipated significant declines in future sales and profitability.
- 6Research and Development (R&D) expenses decreased by 3% to $909 million, partly due to a significant upfront payment in the prior year's quarter related to YERVOY.
- 7Cash and cash equivalents decreased significantly to $2.31 billion from $5.78 billion, largely due to the Inhibitex acquisition.